Neogene Therapeutics develops engineered T cell receptor therapies that specifically target neo-antigens, which are mutated proteins found in solid tumors. This approach aims to enhance the immune response in cancer patients, providing a personalized treatment option for those with difficult-to-treat cancers.
Funding
$125M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
ECJCFounders
Product
Problem
Solid tumors present a significant challenge in cancer treatment due to their complex and heterogeneous nature, often evading traditional therapies. Current cancer treatments may not effectively target the unique mutations present in individual tumors, leading to limited efficacy and potential for recurrence. The lack of personalized treatment options for solid tumors hinders the ability to specifically target and eliminate cancer cells while minimizing harm to healthy tissues.
Solution
Neogene Therapeutics is developing engineered T cell receptor (TCR) therapies designed to target neoantigens, which are unique mutated proteins found on the surface of solid tumor cells. These personalized therapies aim to enhance the patient's immune response by equipping T cells with the ability to specifically recognize and destroy cancer cells expressing these neoantigens. By targeting neoantigens, Neogene's approach seeks to provide a more precise and effective treatment option for patients with solid tumors, potentially overcoming the limitations of conventional cancer therapies. The engineered TCRs are designed to bind with high affinity to the neoantigens, triggering a targeted immune response that eliminates cancer cells while sparing healthy tissue.
Target Audience
The primary target audience includes cancer patients with solid tumors who have limited treatment options and clinicians specializing in oncology and personalized cancer therapies.
Features
- Engineered T cell receptor (TCR) therapies targeting neoantigens on solid tumors
- Personalized treatment approach based on individual tumor mutations
- Enhanced T cell recognition and destruction of cancer cells
- High-affinity TCR binding to neoantigens for targeted immune response